← Eichor
Study identifier: NCT06489873 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Lutein, Zeaxathin, and Fish Oil Supplementation

Condition: Cognitive Performance · Age-Related Macular Degeneration · Bone Loss  ·  Sponsor: Texas A&M University

PhaseNA
Planned participants80
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. Participants will be asked to take either a LZF supplement or placebo daily for 6 months.

This description comes directly from the study's public registry record.

Talk to the study team

Karen M Beathard, PhD  ·  979-220-2281  ·  karen-beathard@tamu.edu

Steven E Riechman, PhD  ·  979-862-3213  ·  sriechman@tamu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Gilchrist BuildingCollege Station, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06489873